Fairvalue-Calculator Fairvalue-Calculator
EN DE

Corbus Pharmaceuticals Holdings (CRBP) Fair Value & Analysis

Healthcare · US · Market cap $153M

Price$8.18
Fair Value$7.89
Upside-3.5%
Quality95/100
Evidence: Low Range $5.21 – $9.87

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Corbus Pharmaceuticals Holdings (CRBP) currently trades at $8.18, while our model-based Fair Value estimate is $7.89 — implying the stock looks roughly 3.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Corbus Pharmaceuticals Holdings (CRBP) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $7.89 versus a price of $8.18 — about −3% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CRBP?
Our 21-model fair value for Corbus Pharmaceuticals Holdings is $7.89 (as of Jun 25, 2026), built from audited fundamentals. The current price is $8.18.
What is the quality score of CRBP?
Corbus Pharmaceuticals Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.